Windward Bio priced its IPO at $17 per share, selling about 10.3 million shares and raising roughly $175 million from public investors. A concurrent $50 million private placement from Sanofi brings expected gross proceeds to $225 million.
The Basel-based biotech is developing long-acting antibody medicines for respiratory and dermatologic diseases. Its shares are set to trade on Nasdaq under ticker WWB; underwriters also have an option to buy additional shares that could bring in about $26 million more.
Boston-based Rezera, formerly NodThera, postponed its planned IPO, citing current market conditions. It had been targeting an offering of about $181–$200 million to fund development of its NLRP3 inhibitor, including plans to advance it toward Phase 3 testing.
Rezera said it would continue to consider financing options, including a future public offering. The delay highlights a selective market for biotech listings, even as Windward’s offering went ahead.
Sources:
Sanofi-backed Windward hits $225M IPO goal to advance ...
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
Windward Bio's Stock Market Debut Reels In $225M for Better Biologic Drugs
Windward raises $175M in IPO, adds $50M from Sanofi - European Biotechnology Magazine
Windward Bio Announces Pricing of Initial Public Offering
Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China
Windward Bio prices IPO at $17.00 per share to raise $225 million
Rezera Delays IPO Due to Market Conditions Ahead of Announced Trading Start
Windward Bio Hits $225 Million IPO Goal, Funding China-Licensed Respiratory Programs
November 2026 - European Biotechnology Magazine
Healthcare Stocks In Focus: WWB Surges 40%, LFMD Gains 30%, SSII Rises 20%, TNDM Advances 14%
Windward's $175M IPO gets boost from Sanofi as Rezera offering stalls
RZRA IPO News - Inflammatory disease biotech Rezera postpones $200 million IPO
Windward prices $175M IPO to advance China-licensed lung drugs — Financial News Analysis | AlphAI